These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18702350)

  • 1. [Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration].
    Tano Y;
    Nippon Ganka Gakkai Zasshi; 2008 Jul; 112(7):590-600. PubMed ID: 18702350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES; Adamis AP; Cunningham ET; Feinsod M; Guyer DR;
    N Engl J Med; 2004 Dec; 351(27):2805-16. PubMed ID: 15625332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    ; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
    Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial].
    Pegaptanib Sodium Multi-center Study Group
    Nippon Ganka Gakkai Zasshi; 2011 Feb; 115(2):122-33. PubMed ID: 21400918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Schiller DS
    Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
    Williams AJ; Fekrat S
    Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M; Feucht N; Huebner M; Lohmann C
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
    Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
    Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.
    Gonzales CR;
    Retina; 2005; 25(7):815-27. PubMed ID: 16205558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
    Atmani K; Coscas F; Coscas G; Soubrane G
    Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA; Hassan TS; Williams GA
    Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.
    Bennett MD; Yee W; Bryan JS
    Retina; 2008; 28(7):976-80. PubMed ID: 18698300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study.
    Weber PA; Wirostko BM; Xu X; Goss TF; Zlateva G
    BMC Ophthalmol; 2010 Feb; 10():2. PubMed ID: 20144224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
    Larsen M; Sander B; Villumsen JE; Haamann PH; la Cour M; Lund-Andersen H;
    Ugeskr Laeger; 2005 Aug; 167(35):3301-5. PubMed ID: 16138974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical experience with pegaptanib in the treatment of age-related macular degeneration (AMD)].
    Thelen U
    Klin Monbl Augenheilkd; 2010 Jan; 227(1):67-72. PubMed ID: 19842076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.